InjectionClinical Overview
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered by subcutaneous injection 15 to 30 minutes before meals (for regular/premixed) or immediately before meals (for rapid analogues). Rotate injection sites systematically across the abdomen, thighs, buttocks, and upper arms. Gently invert cloudy NPH/biphasic suspensions 10-20 times before each dose to resuspend uniformly; do not shake vigorously.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia (tremor, diaphoresis, palpitations, confusion), localized lipodystrophy, injection site redness, weight gain. Rare/Severe: Severe hypoglycemic coma, severe hypokalemia, and systemic hypersensitivity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
High-alert medication; verify dose, units, and syringe scale (U-40 vs U-100) carefully before every injection. Always carry rapid-acting oral glucose or candy. Do not freeze. Unopened vials refrigerated (2-8°C); in-use vials room temperature (<25-30°C) for 28-42 days. Rotate injection sites to prevent lipohypertrophy.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Soluble Insulin Injection 40 IU per ml (R-DNA Origin)
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.
Biphasic Isophane Insulin Injection 40 IU/ml (30/70)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Biphasic Isophane Insulin Injection 100 IU/ml (30/70)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Soluble Insulin Injection 100 IU per ml (R-DNA Origin)
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.